A post hoc analysis of the SELECT trial suggests that semaglutide 2.4 mg is associated with a significantly lower incidence of obstructive sleep apnea in adults with overweight or obesity and established cardiovascular disease. While these findings are promising, Novo Nordisk notes that semaglutide is not currently approved to treat obstructive sleep apnea and further research is required.
Flinders University researchers have led a clinical trial examining how a commonly prescribed ‘sleeping pill’ affects sleep, breathing, and next‑day performance.
'The medical device industry has long assumed that mass production and true personalization are incompatible. FormFit proves they are not.'
This chart highlights key specifications and features among CPAP pillows, including adjustability, dimensions, materials, washability, and price.
The acquisition of PONM gives Nexalin ownership of the AI-integrated software supporting its HALO Clarity program, preparing for a 160-participant trial for moderate-to-severe insomnia.
Josza brings extensive experience across the medical and dental device industries to his new leadership role, effective May 11.
The new dual-product system aims to support the 24-hour wellness cycle, accompanied by a strategic partnership with the Calm app to offer curated sleep content.
A retrospective study explores how surgical and pharmacologic weight-loss strategies stack up in cost, effectiveness, and health outcomes.
A mastery-based cognitive-behavioral model centers on "nightmare efficacy" to help clinicians create personalized treatment plans for youth.